Gilead Sciences Past Earnings Performance

Past criteria checks 1/6

Gilead Sciences has been growing earnings at an average annual rate of 3.5%, while the Biotechs industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 5.1% per year. Gilead Sciences's return on equity is 2.6%, and it has net margins of 1.8%.

Key information

3.5%

Earnings growth rate

4.1%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate5.1%
Return on equity2.6%
Net Margin1.8%
Next Earnings Update08 Aug 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Gilead Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XTRA:GIS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2427,4504855,5805,778
31 Dec 2327,1165,6655,5375,758
30 Sep 2327,3915,8766,5025,880
30 Jun 2327,3825,4846,4015,557
31 Mar 2327,0435,5835,9095,280
31 Dec 2227,2814,5925,6734,998
30 Sep 2227,1363,3345,3034,768
30 Jun 2227,5154,1375,2804,727
31 Mar 2227,4724,5155,2744,714
31 Dec 2127,3056,2255,2464,601
30 Sep 2127,4827,3945,0834,655
30 Jun 2126,6385,1624,9994,713
31 Mar 2125,5643014,8874,924
31 Dec 2024,6891235,1124,927
30 Sep 2023,1471,2684,6254,560
30 Jun 2022,174-2574,5714,432
31 Mar 2022,7164,9624,4274,002
31 Dec 1922,4495,3864,3814,055
30 Sep 1922,3652,6934,3084,086
30 Jun 1922,3575,9554,2043,995
31 Mar 1922,3205,8924,0894,318
31 Dec 1822,1275,4554,0563,920
30 Sep 1822,2811,5874,1774,218
30 Jun 1823,1972,2084,1084,068
31 Mar 1824,6903,4644,0253,740
31 Dec 1726,1074,6283,8783,734
30 Sep 1727,47811,6013,6183,591
30 Jun 1728,46612,2133,5703,826
31 Mar 1729,10112,6373,5634,446
31 Dec 1630,39013,5013,3984,666
30 Sep 1631,57615,0763,4724,416
30 Jun 1632,37116,3463,5444,135
31 Mar 1632,83917,3413,4663,469
31 Dec 1532,63918,1083,4263,014
30 Sep 1531,44716,9123,2362,952
30 Jun 1529,19415,0433,2782,839
31 Mar 1527,48514,2073,0802,608
31 Dec 1424,89012,1012,9832,854
30 Sep 1420,6969,4062,5612,409
30 Jun 1417,4377,4632,0232,295
31 Mar 1413,6694,5801,8142,220
31 Dec 1311,2023,0751,6992,120
30 Sep 1310,5853,0461,5381,952
30 Jun 1310,2292,9331,4511,902

Quality Earnings: GIS has a large one-off loss of $8.3B impacting its last 12 months of financial results to 31st March, 2024.

Growing Profit Margin: GIS's current net profit margins (1.8%) are lower than last year (20.6%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: GIS's earnings have grown by 3.5% per year over the past 5 years.

Accelerating Growth: GIS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: GIS had negative earnings growth (-91.3%) over the past year, making it difficult to compare to the Biotechs industry average (3%).


Return on Equity

High ROE: GIS's Return on Equity (2.6%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.